Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaDeveloping strategies in the immunotherapy of leukemiasRapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemiaThe clinical significance of patients' sex in chronic lymphocytic leukemia.Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case ReportThe CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelA phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patientsIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a reviewCurrent and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.The spectrum of use of rituximab in chronic lymphocytic leukemiaRole of rituximab in first-line treatment of chronic lymphocytic leukemia.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaChoosing first-line therapy for chronic lymphocytic leukemia.Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's MacroglobulinemiaThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Immunotherapy targets in pediatric cancer.Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.Initial treatment of CLL: integrating biology and functional status.Therapeutic advancement of chronic lymphocytic leukemia.Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US iChronic lymphocytic leukemia: inception to cure: are we there?Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinibThe long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaPersonalized medicine in CLL: current status and future perspectives.
P2860
Q24203027-4AB6B3A4-3F9C-4B52-92EC-6C991CC5B812Q26996310-74C2624D-85F3-4286-8F8F-E29B4F159A37Q30417730-68011A95-2F49-477B-9A06-1E41AFFB64ADQ33406478-DE19E41F-7D36-492B-987D-502C06436742Q33417117-6618FB8E-4677-4475-A033-E19EB369BEF2Q33437042-3A9CF18D-11B9-4D0B-8374-904A83AC10A3Q33695983-E3270B53-9DFC-455A-9E71-9D3A86A72345Q33698000-F23825B5-1428-4A36-BB3F-1DAB90E0F9BAQ33875604-E85080D4-BBBB-4B7B-BB12-7C51E5210586Q33880538-9A2EB771-3F07-4982-991C-F1D691A1979EQ33903379-C485AA61-81D6-4D40-A350-FCCA3AAA5DCBQ34009003-6A947B51-9F8F-4410-A8D1-E29F254771DBQ34172063-0225FEBE-120F-4BF5-8836-AFCEFEEE73AAQ34348572-7EBCBF07-4793-4AC9-A8CE-C8E616D68EB1Q34440110-F4ABABD2-A8D7-4E6B-8863-9E11203C3A2CQ34510030-922A1C6D-FF88-4792-A575-F37CDA2FBE7AQ34574147-5989A482-9C60-458A-B983-28D6945DBB3FQ34625543-6A1AF728-0B75-4A48-89A3-B5699FAF6A68Q34769213-A75376D8-B2B3-4F8F-AD61-3C00E798070EQ35033519-25361125-8662-4481-812E-0DD32C19CB5FQ35124844-6C935000-9C48-4161-84A8-885EA845FA09Q35153656-97E13048-6C1C-443C-A5F6-1750AC676C40Q35450520-0628DC38-D301-4EE0-BA86-2CD3866D7A84Q35683808-46ED708C-A173-4D3D-995E-F8D01CBE03F1Q35971029-1F38A57A-DAAC-4154-9B0D-29058FE7895FQ36097697-CE7D07F6-A729-45F7-BBE7-EA2F6593BAD9Q36218799-B8D1641E-5E41-41E6-BA88-3108B6BACB77Q36219647-27CE43B3-D8CC-4466-9E14-155E8C53950EQ36300303-919DCCF4-C726-436E-A71C-D72ACA7A95BFQ36397924-0A573DE4-961B-48C8-B11E-FD1905182C71Q36609259-DE06BD0E-8EB4-4BEF-8942-4C36C7B13810Q36692782-AB1EC02D-FE13-466B-A71B-613C3ECD710EQ36782516-3839A014-EE70-4190-AA9F-F08BECCD62B2Q36800105-BDA2AA6F-5F4D-4E93-B76A-033FBEC16FA4Q36826893-9957BCFC-3BEE-4C6A-B0CC-79CF6E732CB1Q37036898-644FBFB5-4CCE-477E-9116-C6B7057ED1C8Q37049035-10051382-0815-44FE-89B9-C4B694646719Q37154344-2D921DF5-97DE-43E1-8B9D-208B0EB0CC50Q37257024-4CEE974C-1201-4952-AB12-F7BDFE5EB6E8Q37412148-E804C951-EB22-4227-A19B-3C03039C15E6
P2860
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@ast
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@en
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@nl
type
label
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@ast
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@en
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@nl
prefLabel
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@ast
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@en
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@nl
P2093
P2860
P50
P356
P1476
Chemoimmunotherapy with fludar ...... follow-up of CALGB study 9712
@en
P2093
Amy S Ruppert
Bercedis L Peterson
Jennifer A Woyach
John G Gribben
Kanti R Rai
Vicki A Morrison
P2860
P304
P356
10.1200/JCO.2010.31.1811
P407
P577
2011-02-14T00:00:00Z